|Table of Contents|

Relationship between serum miR-25-3p,CXCL12 level and prognosis of patients with non-small cell lung cancer after thoracoscopic lobectomy

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2024 09
Page:
1643-1648
Research Field:
Publishing date:

Info

Title:
Relationship between serum miR-25-3p,CXCL12 level and prognosis of patients with non-small cell lung cancer after thoracoscopic lobectomy
Author(s):
CHEN Bin; ZHONG Chonghao; FANG Zhao; CHEN Tao; WU Wei
Department of Cardiothoracic Surgery,Affiliated Central Hospital of Jiangnan University/The Second People's Hospital of Wuxi,Jiangsu Wuxi 214000,China.
Keywords:
non-small cell lung cancer; miR-25-3p; spinal cord chemokine CXC ligand 12; thoracoscopic lobectomy; prognosis; predictive value
PACS:
R734.2
DOI:
10.3969/j.issn.1672-4992.2024.09.012
Abstract:
Objective:To analyze the relationship between serum miR-25-3p, spinal cord chemokine CXC ligand 12 (CXCL12) and prognosis of patients with non-small cell lung cancer (NSCLC) after thoracoscopic lobectomy.Methods:A total of 175 patients with NSCLC admitted to the hospital from February 2017 to July 2020 were selected,all of whom underwent thoracoscopic lobectomy.Serum miR-25-3p and CXCL12 levels were detected before operation.After 3 years of follow-up,patients were divided into poor prognosis group (recurrence and metastasis) and good prognosis group (non-recurrence and metastasis) according to the prognosis.The levels of serum miR-25-3p and CXCL12 in the poor prognosis group and the good prognosis group were compared,and the clinical data of the poor prognosis group and the good prognosis group were compared,and the influencing factors of the poor prognosis in patients with NSCLC after surgery were analyzed.The predictive value of serum miR-25-3p and CXCL12 levels and their combination on postoperative poor prognosis of patients with NSCLC were analyzed.Results:After 3 years of follow-up,6 of 175 patients were lost to follow-up,the follow-up rate was 96.57%,including 31 patients with recurrence and metastasis,the recurrence and metastasis rate was 18.34%,and the remaining 138 patients did not have recurrence and metastasis,the median time of recurrence and metastasis was 24.75 months (95%CI:18.32~28.47).The levels of miR-25-3p and CXCL12 in the poor prognosis group were higher than those in the good prognosis group (P＜0.05).The proportion of stage Ⅱ and low differentiation cases in poor prognosis group was higher than that in good prognosis group (P＜0.05).Multivariate Cox regression analysis results showed that stage Ⅱ (HR=3.827,95%CI:1.682~8.705),low differentiation (HR=3.466, 95%CI:1.524~7.884),serum miR-25-3p (HR=2.732,95%CI:1.201~6.215) and serum CXCL12 (HR=3.152,95%CI:1.386~7.170) were the influential factors for poor prognosis of patients with NSCLC after surgery (P＜0.05).Receiver operating characteristic curve (ROC) results showed that the sensitivity of serum miR-25-3p and CXCL12 levels and their combination in predicting postoperative poor prognosis of NSCLC patients were 80.65% (95%CI:0.627~0.853) and 83.87% (95%CI:0.641~0.869),93.55% (95%CI:0.782~0.973),the specificity was 78.26% (95%CI:0.602~0.835),76.09% (95%CI:0.584~0.791),91.30% (95%CI: 0.769~0.934),the area under the curve (AUC) values were 0.767,0.755 and 0.908 (P＜0.05),and the AUC values of the two combined were higher (P＜0.05).Conclusion:Preoperative detection of serum miR-25-3p and CXCL12 levels can be used to predict the prognosis of NSCLC patients after thoracoscopic lobectomy,and the combination of miR-25-3p and CXCL12 levels has higher predictive value.

References:

［1］MITHOOWANI H,FEBBRARO M.Non-small-cell lung cancer in 2022:a review for general practitioners in oncology［J］.Curr Oncol,2022,29(3):1828-1839.
［2］DENG HY,QIU XM,ZHU DX,et al. Video-assisted thoracoscopic sleeve lobectomy for centrally located non-small cell lung cancer:a meta-analysis［J］.World J Surg, 2021,45(3):897-906.
［3］GEROPOULOS G,ESGIAN SM,SKARENTZOS K,et al.Video-assisted thoracoscopic versus open sleeve lobectomy for non-small cell lung cancer:a systematic review and meta-analysis from six comparative studies［J］.Asian Cardiovasc Thorac Ann,2022,30(8):881-893.
［4］SINGH A,SINGH AK,GIRI R,et al.The role of microRNA-21 in the onset and progression of cancer［J］.Future Med Chem,2021,13(21):1885-1906.
［5］BAHREINI F,RAYZAN E,RRZAEI N.microRNA-related single-nucleotide polymorphisms and breast cancer［J］.J Cell Physiol,2021,236(3):1593-1605.
［6］NG L,SIN RW,CHEUNG DH,et al.Serum microRNA levels as a biomarker for diagnosing non-alcoholic fatty liver disease in Chinese colorectal polyp patients［J］.Int J Mol Sci, 2023,24(10):9084.
［7］陈文霞,刘艳红,肖兴国,等. 结肠癌患者血清miR-17-5p、miR-25-3p的表达水平及临床意义［J］. 中国老年学杂志,2022,42(9):2099-2102. CHEN WX,LIU YH,XIAO XG,et al.Expression levels of serum miR-17-5p and miR-25-3p in patients with colon cancer and their clinical significance［J］.Chinese Journal of Gerontology, 2019,42(9):2099-2102.
［8］蒋雅玲,胡学丽,陈辉,等.趋化因子CXCL12及其配体CXCR4、CXCR7对HER2阳性乳腺癌细胞生物学功能的影响［J］.中国免疫学杂志,2022,38(14):1722-1727. JIANG YL,HU XL,CHEN H,et al.Effect of chemokine CXCL12 and its ligands CXCR4 and CXCR7 on biological function of HER2-positive breast cancer cells ［J］.Chinese Journal of Immunology, 2022,38(14):1722-1727.
［9］中华医学会肿瘤学分会,中华医学会杂志社.中华医学会肿瘤学分会肺癌临床诊疗指南（2021版）［J］.中华医学杂志,2021,101(23):1725-1757. Oncology Branch of Chinese Medical Association,Journal of Chinese Medical Association.Guidelines for clinical diagnosis and treatment of lung cancer,Chinese society of oncology (2021 edition)［J］.Chinese Medical Journal,2021,101(23):1725-1757.
［10］戴亮,闫万璞,康晓征,等.基于416例Ⅰ期NSCLC肺叶切除术后随访结果探讨早期NSCLC术后随访策略［J］. 中国肺癌杂志,2018,21(3):199-203. DAI L,YAN WP,KANG XZ,et al.Study on postoperative follow-up strategy of early stage NSCLC based on 416 patients with stage Ⅰ NSCLC after lobectomy ［J］.Chinese Journal of Lung Cancer,2018,21(3):199-203.
［11］DURANTE G,BROSEGHINI E,COMITO F,et al.Circulating microRNA biomarkers in melanoma and non-melanoma skin cancer［J］.Expert Rev Mol Diagn,2022,22(3):305-318.
［12］PAN G,LIU Y,SHANG L,et al.EMT-associated microRNAs and their roles in cancer stemness and drug resistance［J］.Cancer Commun (Lond),2021,41(3):199-217.
［13］SHI L,CAO Y,YUAN W,et al.Exosomal circRNA BTG2 derived from RBP-J overexpressed-macrophages inhibits glioma progression via miR-25-3p/PTEN［J］.Cell Death Dis,2022,13(5):506.
［14］PIRLOG R,CHIROI P,RUSU I,et al.Cellular and molecular profiling of tumor microenvironment and early-stage lung cancer［J］.Int J Mol Sci,2022,23(10):5346.
［15］SUN B,HU N,CONG D,et al.microRNA-25-3p promotes cisplatin resistance in non-small-cell lung carcinoma (NSCLC) through adjusting PTEN/PI3K/AKT route［J］.Bioengineered,2021,12(1):3219-3228.
［16］LIU Y,HU Y,ZHAO C,et al.CircRNA B cell linker regulates cisplatin sensitivity in nonsmall cell lung cancer via microRNA-25-3p/BarH-like homeobox 2 axis［J］.Anticancer Drugs,2023,34(5):640-651.
［17］WEI R,ZHOU Y,LI C,et al.Ketogenesis attenuates KLF5-dependent production of CXCL12 to overcome the immunosuppressive tumor microenvironment in colorectal cancer［J］.Cancer Res,2022,82(8):1575-1588.
［18］HEIDEGGER I,FOTAKIS G,OFFERMANN A,et al.Comprehensive characterization of the prostate tumor microenvironment identifies CXCR4/CXCL12 crosstalk as a novel antiangiogenic therapeutic target in prostate cancer［J］.Mol Cancer,2022,21(1):132.
［19］LI J,SHU X,XU J,et al.S100A9-CXCL12 activation in BRCA1-mutant breast cancer promotes an immunosuppressive microenvironment associated with resistance to immunotherapy［J］.Nat Commun,2022,13(1):1481.
［20］WU J,LIU X,WU J,et al.CXCL12 derived from CD248-expressing cancer-associated fibroblasts mediates M2-polarized macrophages to promote nonsmall cell lung cancer progression［J］.Biochim Biophys Acta Mol Basis Dis,2022,1868(11):166521.

Memo

Memo:
江苏省自然科学基金(编号：BK20211132)
Last Update: 2024-03-29